Fig. 1

Schematic diagram of HFA 10-2 tests used for analysis in the clinical trial and in the current post hoc analysis. *¹The screening Humphrey visual-field (HFA 10-2) test before registration was used for eligibility decisions at enrollment, for allocation to study drug groups, and as baseline data at the start of the clinical trial. The HFA10-2 test, conducted within 30 days of drug administration, was eligible for inclusion in the clinical trial screening and allocation and for baseline data. *²Analysis of data before the start of the clinical trial. The number and ratio of eyes with paradoxically increased MD or TPS values were evaluated using the HFA10-2 tests before the start of the clinical trial. HFA10-2 results at the start of the clinical trial (0, 0 W) as well as one time before (− 1), two times before (− 2), and three times before (− 3) the start of the clinical trial were analyzed. *³MD slope before the start of the clinical trial was calculated using MD values of HFA10-2 tests observed up to 3 years prior to inclusion in the clinical trial, including the result at the time of enrollment/allocation. *⁴HFA10-2 results from 13 weeks after starting the study drug administration until the end of the clinical trial were analyzed separately, excluding the HFA10-2 data at the eligibility screening.